Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ORGANON & CO.

(OGN)
  Report
Real-time Estimate Cboe BZX  -  11:40 2022-09-28 am EDT
24.40 USD   +0.58%
09/26Organon Canada reinforces the need to raise awareness and access for contraception methods with nearly half of pregnancies unplanned
AQ
09/13ObsEva to Terminate Chief Strategy Officer, 70% of Staff Amid Restructuring
MT
09/06Piper Sandler Upgrades Organon & Co. to Overweight From Neutral, Adjusts Price Target to $34 From $37
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Organon, Samsung Bioepis Say FDA Approves High-Concentration Biosimilar Hadlima

08/17/2022 | 09:06am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ORGANON & CO. 0.62% 24.43 Delayed Quote.-20.33%
SAMSUNG ELECTRONICS CO., LTD. -2.40% 52900 End-of-day quote.-32.44%
All news about ORGANON & CO.
09/26Organon Canada reinforces the need to raise awareness and access for contraception meth..
AQ
09/13ObsEva to Terminate Chief Strategy Officer, 70% of Staff Amid Restructuring
MT
09/06Piper Sandler Upgrades Organon & Co. to Overweight From Neutral, Adjusts Price Target t..
MT
08/18Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HU..
AQ
08/17Organon, Samsung Bioepis Say FDA Approves High-Concentration Biosimilar Hadlima
MT
08/17Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HU..
BU
08/17Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration Hu..
CI
08/08Goldman Sachs Trims Organon & Co's Price Target to $38 From $41, Keeps Buy Rating
MT
08/05BofA Securities Downgrades Organon to Neutral From Buy, Adjusts Price Target to $37 Fro..
MT
08/05ORGANON & CO. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
More news
Analyst Recommendations on ORGANON & CO.
More recommendations
Financials (USD)
Sales 2022 6 241 M - -
Net income 2022 988 M - -
Net Debt 2022 7 792 M - -
P/E ratio 2022 6,17x
Yield 2022 4,71%
Capitalization 6 170 M 6 170 M -
EV / Sales 2022 2,24x
EV / Sales 2023 2,05x
Nbr of Employees 9 300
Free-Float 99,9%
Chart ORGANON & CO.
Duration : Period :
Organon & Co. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ORGANON & CO.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 24,26 $
Average target price 37,38 $
Spread / Average Target 54,1%
EPS Revisions
Managers and Directors
Kevin Ali Chief Executive Officer & Director
Matthew M. Walsh Chief Financial Officer
Carrie Smith Cox Chairman
Sandra Milligan Head-Research & Development
Rachel A. Stahler Chief Information Officer
Sector and Competitors
1st jan.Capi. (M$)
ORGANON & CO.-20.33%6 170
JOHNSON & JOHNSON-3.58%433 657
ELI LILLY AND COMPANY11.32%295 599
ROCHE HOLDING AG-17.54%259 622
ABBVIE INC.4.67%250 575
PFIZER, INC.-25.33%247 449